Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. Its offerings include Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment blood test; PrecisionCHD, an integrated epigenetic-genetic blood test for detecting CHD; and Actionable Clinical Intelligence, a platform providing epigenetic and genetic insights to clinicians for chronic care management. The company also offers CardioInnovate360, a research-use-only solution for discovering and validating biopharmaceuticals for cardiovascular diseases, and HeartRisk, a SaaS cardiovascular risk intelligence platform. It serves telemedicine providers, provider organizations such as concierge practices and longevity clinics, and employer organizations. Founded in 2017, it is headquartered in Chicago, Illinois.